Published in Biomed Pharmacother on May 01, 2001
Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol (2005) 1.32
Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device. Br J Haematol (2008) 0.95
Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J Gene Med (2009) 0.89
Large Scale Generation and Characterization of Anti-Human CD34 Monoclonal Antibody in Ascetic Fluid of Balb/c Mice. Adv Pharm Bull (2013) 0.88
Dehydrated human amnion/chorion membrane regulates stem cell activity in vitro. J Biomed Mater Res B Appl Biomater (2015) 0.82
Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015). Stem Cell Res Ther (2016) 0.79
Investigating evolutionary perspective of carcinogenesis with single-cell transcriptome analysis. Chin J Cancer (2013) 0.78
Stem cell-based cell therapy for glomerulonephritis. Biomed Res Int (2014) 0.77
Mouse hematopoietic stem cells, unlike human and mouse embryonic stem cells, exhibit checkpoint-apoptosis coupling. Stem Cells Dev (2008) 0.76
Stem cells: An insight into the therapeutic aspects from medical and dental perspectives. J Pharm Bioallied Sci (2015) 0.75
Clinical observation of factors in the efficacy of blood component transfusion in patients following hematopoietic stem cell transplantation. PLoS One (2012) 0.75
Digitalization of a non-irradiated acute myeloid leukemia model. BMC Syst Biol (2016) 0.75
Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet (2000) 3.18
Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer (2008) 1.56
TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol (2008) 1.32
Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A (1997) 1.29
Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol (2001) 1.27
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol (2006) 1.23
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology (2000) 1.23
Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol (2007) 1.20
Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int J Cancer (1997) 1.19
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 1.18
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (2003) 1.16
Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia (2005) 1.16
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents (2010) 1.15
Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest (2000) 1.15
Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med (1990) 1.14
Cyclosporin blood levels do correlate with clinical complications. Lancet (1984) 1.07
Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis (2007) 1.06
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol (2000) 1.00
In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol (1988) 0.99
Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer (2004) 0.99
Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology (2000) 0.98
Breath acetone-aspects of normal physiology related to age and gender as determined in a PTR-MS study. J Breath Res (2009) 0.96
Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol (1987) 0.96
Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br J Haematol (1998) 0.95
Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol (1989) 0.93
Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann Hematol (2001) 0.93
Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis. Ann Hematol (2001) 0.93
Cellular determinants affecting the rate of cytokine in cultures of human hematopoietic cells. Biotechnol Bioeng (1997) 0.91
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). Clin Exp Immunol (1991) 0.90
In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp Hematol (1997) 0.90
Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. Blood (1984) 0.90
Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Ann Hematol (1991) 0.89
Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol (1993) 0.89
Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol (2003) 0.89
BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood (1996) 0.88
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol (2013) 0.87
Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. J Infect Dis (2000) 0.87
Contribution of endothelial cells of hematopoietic origin to blood vessel formation. Circ Res (2001) 0.86
Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res (1985) 0.85
Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor. Immunology (1988) 0.85
Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res (2002) 0.84
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res (2003) 0.84
Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res (1985) 0.81
Vascular endothelial growth factor in serum and in the follicular fluid of patients undergoing hormonal stimulation for in-vitro fertilization. Hum Reprod (1998) 0.81
Feasibility of a multdisciplinary lung cancer videoconference between a peripheral hospital and a comprehensive cancer centre. Oncology (2013) 0.81
Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells (1998) 0.81
Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial. Eur J Cancer (1991) 0.81
Circulating endothelial cells after transplantation. Lancet (2001) 0.81
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells. Cancer Res (1997) 0.80
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol (2010) 0.80
The relationship of HNK-1 (Leu 7) and VEP13 antigens on human cells mediating natural killing. Clin Exp Immunol (1984) 0.80
The kinase inhibitor imatinib--an immunosuppressive drug? Curr Cancer Drug Targets (2007) 0.80
Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke (2001) 0.79
Minimal interferon-alpha doses for hairy cell leukemia. Blood (1990) 0.79
Large granular lymphocytes: morphological studies. Eur J Immunol (1982) 0.79
A biological approach to optimize interferon treatment in hairy cell leukemia. Immunobiology (1986) 0.79
Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie (2004) 0.79
Bone marrow may be the preferable graft source in recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors. Bone Marrow Transplant (2011) 0.78
Treatment of hairy-cell leukemia with recombinant alpha 2-interferon. Eur J Cancer Clin Oncol (1986) 0.78
Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses (2005) 0.78
Macrophage infiltration in non-Hodgkin's lymphomas: a quantitative in situ study. Immunobiology (1986) 0.78
Recombinant alpha 2 interferon for induction and maintenance of remission in hairy cell leukaemia. Br J Haematol (1985) 0.78
Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. Eur J Haematol (2001) 0.78
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status. Int J Cancer (1988) 0.78
Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology (1987) 0.78
Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20. J Interferon Res (1987) 0.78
Current treatment concepts of Philadelphia-negative MPN. Curr Cancer Drug Targets (2011) 0.77
Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol (1995) 0.77
Expression of c-fos correlates with IFN-alpha responsiveness in Philadelphia chromosome positive chronic myelogenous leukemia. Cytokines Mol Ther (1995) 0.77
Local expression of cytokines in rat bladder carcinoma tissue after intravesical treatment with Nocardia rubra cell wall skeleton and bacille-Calmette-Guerin. Urol Res (1997) 0.77
T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. Int J Lab Hematol (2008) 0.77
Abnormal expansions of granular lymphocytes: reactive lymphocytosis or chronic leukemia? Case report and literature review. Blut (1986) 0.77
[Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Dtsch Med Wochenschr (2004) 0.77
Current and future strategies to block tumor angiogenesis, invasion, and metastasis. World J Urol (1996) 0.77
Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. J Clin Pathol (2004) 0.77
Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. Immunobiology (1990) 0.77
Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes. Biol Blood Marrow Transplant (2004) 0.76
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (2000) 0.76
Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol (2003) 0.76
Platelets and VEGF blood levels in cancer patients. Br J Cancer (1999) 0.76
[Palliative immunotherapy of cancer]. Ther Umsch (2001) 0.76
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol (2013) 0.76
Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol (1993) 0.76
Optimal timing for the collection and in vitro expansion of cytotoxic CD56(+) lymphocytes from patients undergoing autologous peripheral blood stem cell transplantation. J Hematother Stem Cell Res (2001) 0.76
Space flight and growth factors. Lancet (1999) 0.76